On July 31, 2018 Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, reported that it will report second quarter 2018 financial results on Tuesday, August 7, 2018 (Press release, Karyopharm, JUL 31, 2018, View Source [SID1234527975]). Karyopharm’s management team will host a conference call and audio webcast at 8:30 a.m. ET on Tuesday, August 7, 2018 to discuss the financial results and recent business developments.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the conference call, please dial (855) 437-4406 (local) or (484) 756-4292 (international) at least 10 minutes prior to the start time and refer to conference ID 3084449. A live audio webcast of the call will be available under "Events & Presentations" in the Investor section of the Company’s website, View Source An archived webcast will be available on the Company’s website approximately two hours after the event.

On July 31, 2018 ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, reported that the Company will present at the upcoming Canaccord Genuity Growth Conference. The presentation is scheduled for 8:30 a.m. ET on August 8, 2018 (Press release, ImmunoGen, JUL 31, 2018, View Source [SID1234528365]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be accessible live through the "Investors" section of the Company’s website, www.immunogen.com; a replay will be available in the same location for approximately two weeks.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On July 31, 2018 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, reported enrollment has opened for a physician-sponsored clinical trial of WP1066 for the treatment of glioblastoma and brain metastases in adults (Press release, Moleculin, JUL 31, 2018, View Source [SID1234528366]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have been eagerly awaiting the beginning of this physician sponsored clinical trial," commented Walter Klemp, Chairman and CEO of Moleculin. "The trial, which is now listed on clinicaltrials.gov and being conducted at MD Anderson Cancer Center, is now open for enrollment. This is our first investigator initiated trial of WP1066 and an important milestone. Given the unique potential of WP1066, we expect more trials to follow."

The goal of this clinical research study is to find the highest tolerable dose of WP1066 that can be given to patients with recurrent (has returned after treatment) cancerous brain tumors or melanoma that has spread to the brain. The safety of this drug will also be studied.

WP1066 is designed to target the STAT3 pathway in cancer cells, which makes these cells divide, increases new blood vessels to the tumor, causes the cancer cells to move throughout the body and brain, and avoids them being detected by the immune system. We believe that targeting this pathway may cause the immune system to kill the cancer cells.

On July 31, 2018 Oncoceutics, Inc. reported the publication of a scientific research article in the journal Clinical Cancer Research that demonstrates utility for the company’s imipridone portfolio of compounds in neuro-oncology (Press release, Oncoceutics, JUL 31, 2018, View Source [SID1234558367]). Oncoceutics developed this portfolio of chemical compounds that target G protein-coupled receptors (GPCRs) using the unique core chemical structure of the company’s lead compound ONC201.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The article identifies several opportunities to use imipridones against gliomas, including identifying effects on an important gene called c-myc on which many cancers depend and which has been deemed "undruggable." The published results also validate the anti-cancer effects, in patient-derived glioma models, of targeting the dopamine receptor DRD2. This is the GPCR antagonized by both ONC201 and ONC206, the second generation DRD2 antagonist with differentiated receptor pharmacology and drug-like characteristics compared to ONC201. In addition, the article provides clinical rationale for the introduction of ONC206 into the clinic in 2019 to treat gliomas and further connects DRD2 antagonism to the previously described downstream signaling effects.

"It is exciting to see the utility of additional imipridones beyond ONC201 for the treatment of lethal cancers with no curative treatments, such as glioblastoma," said Markus Siegelin, M.D, Assistant Professor of Pathology & Cell Biology at Columbia University who served as a senior corresponding author of the publication. "Our study provides unique insights into the mechanism of DRD2 antagonism resulting in the identification of biomarkers for the imipridone clinical program."

"The imipridone family of compounds contains several new therapeutic concepts for oncology that build out from our understanding of ONC201," said Joshua Allen, Ph.D., Senior Vice President of R&D at Oncoceutics. "These exciting new findings set the stage for the upcoming clinical introduction of ONC206 as the next imipridone to make clinical impact."